Eli Lilly LLY and AbbVie ABBV are U.S.-based pharmaceutical powerhouses with blockbuster drug portfolios, robust pipelines, ...

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Eli Lilly LLY -1.05% ...

Millions more Americans should be taking weight-loss drugs to prevent heart disease, according to the American College of ...

The shipments have vaulted Ireland, a country of only five million people, into the second-largest goods-trade imbalance with the U.S., trailing only China.

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Investing.com -- The American College of Cardiology released new recommendations on Friday stating that millions more ...

McDonald’s has historically been a defensive play for investors because its menu appeals to budget-conscious consumers. However, expanded insurance coverage for GLP-1 drugs, along with discount ...

And more pharma news updates from Pharmalittle.

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.

It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ...

It has been found in a phase I study that patients taking Eli Lilly's investigational obesity drug eloralintide lost more ...

GLP-1 medications such as Wegovy, Mounjaro and Ozempic helped drive a 9% year-over-year increase in U.S. prescription dispensing revenue, which reached $683 billion in 2024.  A separate report found ...